New Biology-Driven Drug Discoveries Needed for Treating of Alzheimer’s

Alzheimer’s disease (AD) is a slowly progressing neurodegenerative disorder that affects millions of people worldwide, leaving behind an immense psychological, emotional, and financial burden on patients, caregivers, and healthcare systems. There are no existing therapies to prevent the onset or...

/ June 17, 2019

Q&A with Dr. Oliver Brain: Unintended Consequences Create a Unique Opportunity to Study Inflammatory Bowel Disease.

Oliver Brain, MRCP, PhD, is a principal investigator at the University of Oxford, Nuffield Department of Clinical Medicine, and a recent winner of an nCounter® Autoimmune Profiling Panel through a NanoString® Grant Program. He took time out from treating patients...

Nanostring Scientists Reveal the “Secret Sauce” in Lysate Protocol Development

https://youtu.be/1q9QHGaeLY4 My name is Chris Merritt. I am a Senior Scientist at NanoString Technologies and work in the R&D division. I've been here for five years now. There was one very specific change we had to make to this lysate...

/ May 29, 2019

Q&A with Dr. Salla Keskitalo: Challenges and Opportunities in Studying Rare and Ultra-rare Autoimmune Diseases

Dr. Salla Keskitalo is a Senior Research Scientist at the University of Helsinki and a recent winner of NanoString’s Autoimmunity Grant Program. She made time to speak with us about her work studying rare and ultra-rare autoimmune diseases. NS: Tell...

Q&A with Drs. Torsten Nielsen and Tony Ng and Angela Goytain: Development of a Sarcoma Gene Fusion Assay Faster Than FISH and Simpler than NGS

The NanoString nCounter is Research Use Only and not for diagnostic use. The views expressed herein are solely those of the interviewed researchers. Torsten Nielsen, MD, PhD is a pathologist and clinical scientist at the University of British Columbia (BC)...